US OptionsDetailed Quotes

FGEN241115P500

Watchlist

0.15
-0.05-25.00%

15min DelayClose Oct 25 16:00 ET

0.15High0.15Low

FibroGen Stock Discussion

Ma-Ke-Mo-Ney

Aug 16 10:19

Give this stock a chance again 💪

$FibroGen (FGEN.US)$ I used to hold it during last year and my patience paid.
hope you can perform again 💪💪💪

Trytosaveabit

Jul 30 15:39

Imagine that!

$FibroGen (FGEN.US)$ Straight down it goes

Trytosaveabit

Jul 30 15:08

Grrr

$FibroGen (FGEN.US)$ Reuters· 1 min ago
FibroGen Inc - Study Did Not Meet Primary Endpoint

TrendTrader

Jul 23 11:40

Over 1.5 looking for 1.8 and 2

$FibroGen (FGEN.US)$ Officer Adib Deyaa purchased 22,123 shares of common stock on Jun 12, 2024 at an average price of $1.17 for a total value of $25,883.91.

Stock Region

Jun 3 17:50

Oncology Company Announces FDA Clearance of New Solid Tumor Treatment

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors.
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...

Trytosaveabit

Jun 3 15:16

Nice!

$FibroGen (FGEN.US)$ See May 7th post! More catalysts possibly to come!

Jaguar8

Jun 3 15:09

NEWS

$FibroGen (FGEN.US)$
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...

bcmuci

Jun 3 15:07

$FibroGen (FGEN.US)$
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials

No comment yet